Personal profile
Main research areas
I am a master student at the University of Copenhagen. I am working with my thesis project in the CO-HEP group at Hvidovre Hospital. My project aims at optimizing a HCV genotype 6a recombinant for cell culture.
Fingerprint
Dive into the research topics where Anna Falden Offersgaard is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein
Radić, L., Offersgaard, A., Kadavá, T., Zon, I., Capella-Pujol, J., Mulder, F., Koekkoek, S., Spek, V., Chumbe, A., Bukh, J., van Gils, M. J., Sanders, R. W., Yin, V. C., Heck, A. J. R., Gottwein, J. M., Sliepen, K. & Schinkel, J., 15 Apr 2025, In: Proceedings of the National Academy of Sciences of the United States of America. 122, 15, p. e2420402122 e2420402122.Research output: Contribution to journal › Journal article › Research › peer-review
1 Citation (Scopus) -
Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection
Wørzner, K., Schmidt, S. T., Zimmermann, J., Tami, A., Polacek, C., Fernandez-Antunez, C., Hartmann, K. T., Jensen, R. F., Hansen, J. S., Illigen, K., Isling, L. K., Erbs, G., Jungersen, G., Rosenkrands, I., Offersgaard, A., Gottwein, J., Holmbeck, K., Jensen, H. E., Ramirez, S. & Follmann, F. & 2 others, , Mar 2025, In: EBioMedicine. 113, 105615.Research output: Contribution to journal › Journal article › Research › peer-review
8 Citations (Scopus) -
SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots
Zhou, Y., Gammeltoft, K. A., Tjørnelund-Sjursen, H. D., Ryberg, L. A., Offersgaard, A., Czarnota, A., Duan, Z., Pham, L. V., Fahnøe, U., Peters, G. H. J., Ramirez, S., Bukh, J. & Gottwein, J. M., Dec 2025, In: Emerging microbes & infections. 14, 1, p. 2552716 2552716.Research output: Contribution to journal › Journal article › Research › peer-review
1 Citation (Scopus) -
An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals
Offersgaard, A., Duarte Hernandez, C. R., Zhou, Y., Duan, Z., Gammeltoft, K. A., Hartmann, K. T., Fahnøe, U., Marichal-Gallardo, P., Alzua, G. P., Underwood, A. P., Sølund, C., Weis, N., Bonde, J. H., Christensen, J. P., Pedersen, G. K., Jensen, H. E., Holmbeck, K., Bukh, J. & Gottwein, J. M., 24 Jul 2024, In: Scientific Reports. 14, 1, p. 17039 17039.Research output: Contribution to journal › Journal article › Research › peer-review
2 Citations (Scopus) -
An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
Offersgaard, A., Duarte Hernandez, C. R., Feng, S., Marichal-Gallardo, P., Holmbeck, K., Pihl, A. F., Fernandez-Antunez, C., Alzua, G. P., Hartmann, K. T., Pham, L. V., Zhou, Y., Gammeltoft, K. A., Fahnøe, U., Schneider, U. V., Pedersen, G. K., Jensen, H. E., Christensen, J. P., Ramirez, S., Bukh, J. & Gottwein, J. M., 17 Feb 2023, In: iScience. 26, 2, p. 105949 105949.Research output: Contribution to journal › Journal article › Research › peer-review
8 Citations (Scopus)